Adverse Events and Compliance Among Inflammatory Bowel Disease Patients Treated With Home- vs Office-Based Biologic Infusions
Inflammatory Bowel Diseases · 2024
DOI: 10.1093/ibd/izad226 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Inflammatory Bowel Diseases, 2024. Verfasst von Christopher J Schmoyer und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, University of Pennsylvania, Philadelphia, PA, USA. Hauptthemen laut MEDLINE: Infliximab, Inflammatory Bowel Diseases, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 13 Literaturangaben.
Themen: Patientensicherheit
Abstract (Originalsprache)
Background
Biologic medications are a common therapy for those with inflammatory bowel disease (IBD). There are limited data on the outcomes of home-based biologic infusions for patients with IBD. The aim of this study was to compare the safety and efficacy of biologic infusions for IBD patients who receive either home- or office-based administration.
Methods
Patients receiving infliximab or vedolizumab were analyzed retrospectively over a period of 152 weeks. Survival free of major adverse events including delayed infusion reaction, steroid initiation, drug discontinuation, or IBD-related emergency department visits, admission, and surgery were compared using a Kaplan-Meier curve. Individual adverse events, infusion-.related quality measures, and markers of patient adherence were analyzed.
Results
Adverse event–free survival was greater among those receiving home-based infusion (n = 154) compared with office-based infusion (n = 133). The office infusion cohort had higher rates of delayed infusion reactions (4 vs 0), IBD-related surgery (6 vs 0), and drug discontinuation (44 vs 35); this was a sicker cohort of patients compared with those in the home infusion group. Home infusion patients were less likely to receive correct weight-based dosing for infliximab (71.7% vs 89.3%), obtain labs for drug monitoring (53.2% vs 71.4%), and adhere to routine clinic visits (37.9% vs 58.1%).
Conclusions
The home-based infusion of biologics for IBD appears safe with lower rates of major adverse events compared with office-based infusions. However, those receiving home infusion were less likely to receive correct weight-based dosing for infliximab and were poorly adherent to routine follow-up.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, University of Pennsylvania, Philadelphia, PA, USA.
- Division of Gastroenterology and Hepatology, Thomas Jefferson University Hospital, Philadelphia, PA, USA.
- Department of Internal Medicine, University of California, Irvine, Irvine, CA, USA.
ORCID-Profile: Christopher J Schmoyer
Zitieren
APA
Schmoyer, C. J., Sun, K., Zack, J., Kumar, P., & Shivashankar, R. (2024). Adverse Events and Compliance Among Inflammatory Bowel Disease Patients Treated With Home- vs Office-Based Biologic Infusions. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izad226
Vancouver
Schmoyer CJ, Sun K, Zack J, Kumar P, Shivashankar R. Adverse Events and Compliance Among Inflammatory Bowel Disease Patients Treated With Home- vs Office-Based Biologic Infusions. Inflammatory Bowel Diseases. 2024. doi:10.1093/ibd/izad226
BibTeX
@article{Schmoyer2024,
author = {Schmoyer, Christopher J and Sun, Kelly and Zack, Jeremy and Kumar, Priyanka and Shivashankar, Raina},
title = {Adverse Events and Compliance Among Inflammatory Bowel Disease Patients Treated With Home- vs Office-Based Biologic Infusions},
journal = {Inflammatory Bowel Diseases},
year = {2024},
doi = {10.1093/ibd/izad226}
}
EUVIMED